Opyl Competitors

Opyl (ASX:OPL) and 1st Group (ASX:1ST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a summary of current ratings and recommmendations for Opyl and 1st Group, as provided by MarketBeat.

Profitability

This table compares Opyl and 1st Group's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Opyl and 1st Group's revenue, earnings per share and valuation.

Opyl has higher earnings, but lower revenue than 1st Group.

Summary

Opyl beats 1st Group on 2 of the 3 factors compared between the two stocks.

Opyl (ASX:OPL) and Alcidion Group (ASX:ALC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Profitability

This table compares Opyl and Alcidion Group's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Opyl and Alcidion Group's top-line revenue, earnings per share (EPS) and valuation.

Opyl has higher earnings, but lower revenue than Alcidion Group.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Opyl and Alcidion Group, as reported by MarketBeat.

Summary

Opyl beats Alcidion Group on 2 of the 3 factors compared between the two stocks.

Binovi Technologies (OTCMKTS:BNVIF) and Opyl (ASX:OPL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Binovi Technologies and Opyl's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Binovi Technologies and Opyl, as reported by MarketBeat.

Valuation and Earnings

This table compares Binovi Technologies and Opyl's gross revenue, earnings per share (EPS) and valuation.

Binovi Technologies has higher earnings, but lower revenue than Opyl.

Summary

Opyl beats Binovi Technologies on 1 of the 1 factors compared between the two stocks.

Opyl (ASX:OPL) and Cann American (CNSX:CNNA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Valuation & Earnings

This table compares Opyl and Cann American's revenue, earnings per share and valuation.

Cann American has lower revenue, but higher earnings than Opyl.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Opyl and Cann American, as provided by MarketBeat.com.

Profitability

This table compares Opyl and Cann American's net margins, return on equity and return on assets.

Summary

Opyl beats Cann American on 1 of the 1 factors compared between the two stocks.

Opyl (ASX:OPL) and CannaOne Technologies (OTCMKTS:CNONF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Opyl and CannaOne Technologies, as reported by MarketBeat.

Earnings & Valuation

This table compares Opyl and CannaOne Technologies' top-line revenue, earnings per share and valuation.

CannaOne Technologies has lower revenue, but higher earnings than Opyl.

Profitability

This table compares Opyl and CannaOne Technologies' net margins, return on equity and return on assets.

Summary

Opyl beats CannaOne Technologies on 1 of the 1 factors compared between the two stocks.

CloudMD Software & Services (OTCMKTS:DOCRF) and Opyl (ASX:OPL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares CloudMD Software & Services and Opyl's revenue, earnings per share (EPS) and valuation.

CloudMD Software & Services has higher earnings, but lower revenue than Opyl.

Analyst Recommendations

This is a breakdown of current ratings for CloudMD Software & Services and Opyl, as reported by MarketBeat.

CloudMD Software & Services currently has a consensus price target of $3.3750, suggesting a potential upside of 117.74%.

Profitability

This table compares CloudMD Software & Services and Opyl's net margins, return on equity and return on assets.